Seoulin Bioscience Co.Ltd Total Liabilities
Seoulin Bioscience Co.Ltd total liabilities. Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has total liabilities worth ₩32.75 Billion KRW (≈ $22.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Seoulin Bioscience Co.Ltd (038070) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Seoulin Bioscience Co.Ltd (2013–2025)
Total liabilities of Seoulin Bioscience Co.Ltd from 2013 to 2025. This chart illustrates how Seoulin Bioscience Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 038070 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Seoulin Bioscience Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dogusan Boru Sanayi ve Ticaret AS
IS:DOGUB
|
Turkey | TL5.03 Million |
|
HUTCHMED China Ltd
LSE:HCM
|
UK | GBX501.83 Million |
|
Boat Rocker Media Inc
TO:BRMI
|
Canada | CA$173.23 Million |
|
KPX Lifescience.Co.Ltd
KQ:114450
|
Korea | ₩15.22 Billion |
|
Mahalaxmi Rubtech Limited
NSE:MHLXMIRU
|
India | Rs332.13 Million |
|
Galaxia SM Inc
KO:011420
|
Korea | ₩7.61 Billion |
|
Transtouch Technology
TWO:3623
|
Taiwan | NT$109.16 Million |
|
Green Resources Public Company Limited
BK:GREEN
|
Thailand | ฿195.49 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Seoulin Bioscience Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Seoulin Bioscience Co.Ltd asset portfolio.
Liquidity & Leverage Metrics
Seoulin Bioscience Co.Ltd Total Liabilities Ratios Explained
Seoulin Bioscience Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seoulin Bioscience Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seoulin Bioscience Co.Ltd (2013–2025)
The table below shows the annual total liabilities of Seoulin Bioscience Co.Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩32.75 Billion ≈ $22.19 Million |
+85.72% |
| 2024-12-31 | ₩17.63 Billion ≈ $11.95 Million |
-43.19% |
| 2023-12-31 | ₩31.04 Billion ≈ $21.03 Million |
-39.24% |
| 2022-12-31 | ₩51.08 Billion ≈ $34.62 Million |
-17.21% |
| 2021-12-31 | ₩61.71 Billion ≈ $41.82 Million |
+236.70% |
| 2020-12-31 | ₩18.33 Billion ≈ $12.42 Million |
-12.73% |
| 2019-12-31 | ₩21.00 Billion ≈ $14.23 Million |
+20.72% |
| 2018-12-31 | ₩17.39 Billion ≈ $11.79 Million |
-11.00% |
| 2017-12-31 | ₩19.54 Billion ≈ $13.24 Million |
+9.39% |
| 2016-12-31 | ₩17.87 Billion ≈ $12.11 Million |
-14.12% |
| 2015-12-31 | ₩20.80 Billion ≈ $14.10 Million |
+18.36% |
| 2014-12-31 | ₩17.57 Billion ≈ $11.91 Million |
-6.62% |
| 2013-12-31 | ₩18.82 Billion ≈ $12.75 Million |
-- |
About Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more